Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026Cardiovascular MedicineOpen Access

TriCValve emerges as a transcatheter alternative for high-risk patients with severe TR.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Tricuspid regurgitation is increasingly recognized, associated with rising mortality, and historically undertreated, prompting review of transcatheter options such as caval valve implantation in high-risk patients.

Design

Clinical case report and narrative review

Key result

Heterotopic implantation of bioprosthetic valves in the vena cava (TriCValve) represents an emerging transcatheter alternative for high-risk patients with severe tricuspid regurgitation.

Authors

VMValerio Massimo MagroNMNicola ManocchioASAndrea Sorbino

Discussion

Loading...

Member takes

Overview

Rising TR mortality trends warrant attention; leaves open whether timely intervention improves outcomes.

Key Points

  • The aim is to analyze the management of tricuspid regurgitation (TR) and the implications of transcatheter interventions.
  • Narrative review of existing literature on tricuspid regurgitation and its treatments, focusing on clinical experiences and outcomes.
  • Examination of different transcatheter devices and their therapeutic approaches in high-risk TR patients.
  • Evidence indicates an increase in TR-related mortality over the past 20 years, necessitating better management strategies.
  • The use of minimally invasive treatments is becoming more prevalent, offering alternatives to traditional surgery for high-risk patients.
  • Heterotopic implantation of bioprosthetic valves offers a new approach to manage TR, potentially improving patient rehabilitation outcomes.

Structured PICO

P
Population
High-risk patients with severe tricuspid regurgitation
I
Intervention
Heterotopic implantation of bioprosthetic valves in the superior and inferior vena cava (TriCValve)

Heterotopic caval valve implantation represents an emerging transcatheter therapeutic option for high-risk patients with severe tricuspid regurgitation who are not candidates for isolated surgery.

Cite This Study

Magro et al. (2026) conducted a review in Tricuspid regurgitation. TriCValve (heterotopic implantation of bioprosthetic valves in the superior and inferior vena cava) was evaluated. Heterotopic implantation of bioprosthetic valves in the vena cava (TriCValve) represents an emerging transcatheter alternative for high-risk patients with severe tricuspid regurgitation.

synapsesocial.com/papers/6a508d096eeac72a437a0c4ehttps://doi.org/10.3390/cardiovascmed29030024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advancements in transcatheter tricuspid valve repair and replacement: a state-of-the-art review with echocardiographic outcomes2025
  2. 2Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?2021 · 71 citations
  3. 3TricValve: A Palliative Therapy for Inoperable Tricuspid Regurgitation2024
  4. 4New Approaches to Treatment of Tricuspid Regurgitation2025 · 1 citations
  5. 5Transcatheter Management of Tricuspid Regurgitation: A Review of Contemporary Evidence2024 · 8 citations